How Effective Is Letrozole for Pregnancy?

Letrozole is one of the most effective oral medications for achieving pregnancy in women who do not ovulate regularly, particularly those with polycystic ovary syndrome (PCOS). A large meta-analysis found that women with PCOS who took letrozole were about 50% more likely to have a live birth compared to those taking clomiphene citrate, the older and historically more common fertility pill. The picture shifts depending on the underlying cause of infertility, though, and letrozole’s advantage shrinks or disappears entirely in some settings.

Where Letrozole Works Best

The strongest case for letrozole is in PCOS, the most common cause of ovulatory infertility. A landmark trial published in the New England Journal of Medicine randomized 750 women with PCOS to receive either letrozole or clomiphene for up to five treatment cycles. About 28% of the letrozole group had a live birth, compared with roughly 19% in the clomiphene group. The cumulative ovulation rate was also higher with letrozole, at about 62% of cycles versus 48%.¹ A later systematic review and meta-analysis pooling data from multiple trials confirmed this advantage, finding letrozole improved ovulation rates, clinical pregnancy rates, and live birth rates compared to clomiphene across the board.²

International clinical guidelines now reflect this evidence. The evidence-based guideline for PCOS management recommends letrozole as first-line pharmacological treatment for ovulation induction in women with PCOS who have no other infertility factors.³ Despite that recommendation, a cross-sectional survey found letrozole was prescribed to only about 15% of women with PCOS seeking fertility treatment, while clomiphene was given to more than a third.⁴ If your doctor starts with clomiphene for PCOS-related infertility, it is worth asking about letrozole.

Unexplained Infertility Is a Different Story

When couples have no identifiable cause for their difficulty conceiving, letrozole does not show the same clear advantage. A major trial compared letrozole, clomiphene, and injectable gonadotropins in women with unexplained infertility. Letrozole produced the lowest live birth rate of the three, at roughly 19% per cycle, compared with about 23% for clomiphene and 32% for gonadotropins. The difference between letrozole and clomiphene alone was not statistically significant, but letrozole clearly fell behind gonadotropins.⁵

A separate systematic review focused specifically on letrozole versus clomiphene for unexplained infertility reached a similar conclusion: no meaningful difference between the two drugs in pregnancy test rates (about 24% versus 23%), clinical pregnancy, live birth, or miscarriage rates.⁶ So while letrozole is a perfectly reasonable option for unexplained infertility, it does not offer the same edge it does in PCOS. The choice between letrozole and clomiphene in this setting often comes down to side effects, cost, and physician preference rather than efficacy.

How Letrozole Works and Why It Helps the Uterine Lining

Letrozole belongs to a class of drugs called aromatase inhibitors. It blocks the final step in estrogen production, temporarily lowering estrogen levels. The brain responds by ramping up its own signals to the ovaries, which stimulates follicle growth and, ideally, ovulation.⁷ Its half-life is short enough that by the time the uterine lining needs to thicken for a potential pregnancy, the drug has mostly cleared the system and estrogen levels rebound naturally.

This matters because one of clomiphene’s drawbacks is its tendency to thin the uterine lining, making it less hospitable for an embryo. Letrozole avoids this problem. Studies comparing the two drugs in women with PCOS have found that the letrozole group had thicker endometrial tissue, better blood flow to the uterus, and higher levels of markers associated with embryo receptivity.⁸ Another randomized study confirmed that the proportion of women showing a favorable multilayered endometrial pattern was significantly higher in the letrozole group (about 78%) compared with the clomiphene group (55%), and pregnancy rates followed suit.⁹ In other words, letrozole’s benefit is not just about making ovulation happen; it also makes the uterus more welcoming once an egg is released.

Letrozole Combined with Intrauterine Insemination

When letrozole is paired with intrauterine insemination (IUI), the timing and size of the dominant follicle turn out to matter quite a bit. A study of over 760 first letrozole-IUI cycles found an inverted U-shaped relationship between follicle size and live birth: women whose lead follicle measured between roughly 19 and 21 mm at the time of the trigger shot were more than twice as likely to deliver a baby compared with those whose follicles were 18 mm or smaller.¹⁰ A separate analysis using propensity score matching found that letrozole-IUI cycles outperformed clomiphene-IUI cycles in both pregnancy and live birth rates, with a lower risk of carrying multiples.¹¹

Adding progesterone support after the IUI also appears to help. A retrospective study of nearly 1,200 letrozole-IUI cycles found that women who received oral progesterone in the second half of their cycle had a live birth rate of about 20%, compared with roughly 15% in those who did not receive it.¹² This is the kind of incremental improvement that can meaningfully shorten the time to pregnancy when multiple cycles are expected.

What Happens When Letrozole Does Not Work

Not every woman ovulates in response to letrozole. Letrozole resistance, meaning failure to ovulate despite taking the medication, occurs in a subset of PCOS patients. Several factors predict who is less likely to respond. Higher body mass index, higher testosterone levels, and elevated anti-Müllerian hormone (AMH) levels are all associated with reduced responsiveness. One study found that an AMH level above about 16 ng/mL was a strong predictor of poor response to letrozole.¹³ A separate study identified late age at first period and higher ratios of certain pituitary hormones as additional risk factors for non-response at the standard 2.5 mg dose.¹⁴

When the standard dose fails, doctors typically escalate the dose in what is called a stair-step protocol, bumping up from 2.5 mg to 5.0 mg and sometimes to 7.5 mg in successive attempts. Stair-step approaches with letrozole achieve ovulation rates in the high 80s to mid-90s percent range, and a consistent finding across studies is that letrozole gets women to ovulation faster than the equivalent clomiphene stair-step protocol.¹⁵ A novel approach that adjusts both dose and duration can shave about 10 days off the time to ovulation compared with the traditional extended regimen, without compromising pregnancy or live birth rates.¹⁶

For women who remain resistant even at higher doses, adding a low-dose steroid like dexamethasone can push the ovaries past the threshold. In a study of 28 letrozole-resistant women, the combination led to ovulation in about 79% of patients, with a cumulative live birth rate of 32%.¹⁷

Safety for the Baby

Early concerns about letrozole and birth defects created a cloud that has taken years to lift. In 2005, the drug’s manufacturer issued a warning against use in premenopausal women, prompted by a single preliminary report suggesting higher malformation rates.¹⁸ Since then, far larger and more rigorous studies have consistently failed to confirm that risk. A study comparing babies born after letrozole, clomiphene, or natural conception found no significant differences in the rate of congenital malformations across the three groups, with the letrozole rate sitting at about 2.5%.¹⁹

A larger analysis looking specifically at outcomes in assisted reproduction found a major anomaly rate of about 1.9% in the letrozole group versus 1.5% in the natural-cycle group, a gap that was not statistically significant after adjusting for other variables.²⁰ A systematic review and meta-analysis that pooled all available evidence found the overall malformation rate after letrozole was about 2.2%, and randomized trials showed no difference compared to clomiphene. In the observational studies, letrozole actually came out slightly better than clomiphene.²¹ The evidence quality is graded as low simply because birth defects are rare events and individual studies are small, but nothing in the accumulated data points to a meaningful risk.

Side Effects for the Woman Taking It

In the short-course fertility setting, letrozole is generally well tolerated. Clinical trials of letrozole for ovulation induction have reported side effect profiles similar to clomiphene, with no serious adverse events and no increase in multiple pregnancies in several head-to-head comparisons.²² Common complaints during the few days of treatment include mild headache, hot flashes, and fatigue. These are typically brief and resolve once the drug clears, which happens quickly given the short course (usually five days per cycle).

It is worth noting that the longer-term side-effect data on letrozole mostly comes from its use in breast cancer treatment, where women take it daily for years. That context produces more pronounced effects like joint pain, fatigue, nausea, and hair thinning.²³ These are not representative of what you would experience taking five pills per month for a few months of fertility treatment.

Letrozole for Fertility Preservation in Cancer Patients

One of letrozole’s most valued roles is in fertility preservation for women diagnosed with hormone-sensitive cancers, especially breast cancer. The concern with standard ovarian stimulation in these patients is that it drives estrogen levels very high, which could theoretically promote cancer growth. Letrozole solves this by keeping estrogen levels suppressed during the stimulation process. A systematic review and meta-analysis found that adding letrozole to stimulation protocols reduced peak estrogen levels to about 28% of what they would be without it, and did so without any negative effect on the number of mature eggs collected.²⁴

The safety signal from longer follow-up is also reassuring. A systematic review of breast cancer patients who underwent ovarian stimulation with letrozole found no decline in relapse-free survival rates compared with women who did not undergo fertility preservation. In the largest included study, cancer recurred in 5.0% of women who received letrozole-assisted stimulation versus 5.5% of those who did not, after an average follow-up of five to seven years.²⁵ A more recent comparison of letrozole versus tamoxifen during egg retrieval found similar oocyte yields between the two approaches, though letrozole kept estrogen levels considerably lower.²⁶

Letrozole and Endometriosis

Endometriosis is another condition where letrozole shows particular promise, though the evidence base is thinner. The theory is straightforward: endometriosis tissue is estrogen-dependent, and letrozole suppresses local estrogen production in endometriotic implants while still allowing the uterine lining to develop normally once the drug clears. In one study of frozen embryo transfer cycles, women with endometriosis who received letrozole achieved a clinical pregnancy rate of about 59%, compared with roughly 29% in controls who did not receive it.²⁷ The sample was small, so these numbers should be interpreted cautiously, but the direction of the finding is biologically plausible and consistent with how letrozole affects endometrial receptivity.

Poor Ovarian Responders

Women who respond poorly to standard ovarian stimulation, typically those with low egg reserves, represent a challenging group. The evidence for letrozole here is mixed. One randomized trial in poor responders undergoing IVF found no significant differences in the number of eggs retrieved, fertilization rates, or clinical pregnancy rates when letrozole was added to a standard stimulation protocol.²⁸ However, a more recent retrospective study found that adding letrozole to a progestin-primed protocol did increase the number of eggs retrieved and mature oocytes in a specific subset of poor responders, those who were older with diminished ovarian reserve. The catch: this did not translate into higher live birth rates.²⁹ Getting more eggs in this population does not always mean getting more babies, a frustrating reality of reproductive medicine.

What It Costs Compared to Alternatives

Letrozole is a generic drug, and in most countries it is inexpensive. An economic analysis comparing letrozole to clomiphene for ovulation induction found that the cost per live birth was actually lower with letrozole, driven almost entirely by its higher pregnancy rate rather than by any difference in medication price. In that study, about 25% of women on letrozole achieved a live birth compared with about 17% on clomiphene, and the average cost per live birth worked out to roughly the same per-cycle spending but fewer cycles needed.³⁰

When used for IUI in unexplained subfertility, the calculation shifts. A cost-effectiveness analysis from Europe found that letrozole-IUI offered only a modest bump in cumulative live birth rates over four cycles compared to clomiphene-IUI (about 32% versus 29%), while injectable gonadotropins reached about 35% but at vastly higher cost. The analysis concluded that letrozole represented the best value for money at most willingness-to-pay thresholds, landing in a sweet spot between the cheapest option (clomiphene) and the most effective but expensive option (gonadotropins).³¹

Why Letrozole Is Still Off-Label in Many Countries

One of the more puzzling aspects of letrozole’s story is that despite being recommended as first-line treatment by international guidelines, it remains an off-label prescription for fertility in the United States and many other countries. Letrozole was originally developed and approved for treating hormone-receptor-positive breast cancer in postmenopausal women. The manufacturer, Novartis, never sought a fertility indication, and after the 2005 teratogenicity scare, the FDA issued a warning against use in premenopausal women. That warning has not been formally reversed, even though the evidence that prompted it has been thoroughly contradicted by subsequent research.

Off-label does not mean unsafe or unproven. Physicians prescribe medications off-label routinely when the evidence supports it, and the accumulated data on letrozole for ovulation induction is now robust. The off-label status does have practical consequences, though: some insurance plans will not cover it for fertility, and the concept introduced over a decade ago of using aromatase inhibitors in place of clomiphene has only slowly diffused into practice.³² The gap between evidence and uptake helps explain why surveys still find clomiphene prescribed more than twice as often as letrozole for PCOS, even though the evidence has favored letrozole for years.